Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.34 |
| ▸ | SGMS2 | Q8NHU3 | 2/20 | 0.33 |
| ▸ | KIT | P10721 | 2/20 | 0.33 |
| ▸ | KDR | P35968 | 2/20 | 0.33 |
| ▸ | BRD4 | O60885 | 2/20 | 0.32 |
| ▸ | SGMS1 | Q86VZ5 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2628035 | 0.88 | KCNA5 (0.42) | SMN1; SMN2KCNA5SGMS2SGMS1 | |
| SCHEMBL1478346 | 0.88 | KCNA5 (0.47) | TP53SMN1; SMN2KCNA5SGMS2SGMS1 | |
| SCHEMBL2633191 | 0.76 | KCNA5 (0.56) | KCNA5SGMS2SGMS1 | |
| SCHEMBL1478453 | 0.72 | KCNA5 (0.41) | TP53SMN1; SMN2KCNA5SGMS2SGMS1 | |
| SCHEMBL18727704 | 0.69 | KCNA5 (0.46) | KCNA5SGMS2KDRSGMS1 | |
| SCHEMBL18727490 | 0.67 | ELANE (0.45) | SMN1; SMN2KCNA5SGMS2SGMS1 | |
| SCHEMBL2628025 | 0.65 | SLC6A2 (0.43) | SLC6A2SLC6A4 | |
| SCHEMBL12426072 | 0.63 | SGMS2 (0.39) | TP53SMN1; SMN2KCNA5SGMS2KIT | |
| SCHEMBL1478103 | 0.61 | KCNA5 (0.61) | KCNA5SGMS2SGMS1 | |
| SCHEMBL1478104 | 0.61 | KCNA5 (0.61) | KCNA5SGMS2SGMS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8357809-B2 | Acyclic IKur inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-22 | — | — | US | disclosed |
| US-20120094983-A1 | ACYCLIC IKUR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094983-A1 | ACYCLIC IKUR INHIBITORS | KCNH2, KCNJ2, KCNH3 | SLC6A2 4114/4885SLC6A4 2768/4885TP53 3042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.